Build · Owkin
Boehringer Ingelheim used Owkin's K Pro multi-omic reports to prioritize targets and find spatially informed patient-selection biomarkers.
Bulk RNA sequencing did not capture patient heterogeneity or spatial context well enough for target prioritization. Owkin delivered K Pro Multi-omic Reports on its MOSAIC platform, with spatial transcriptomics across 10 cancer indications and Pathology Explorer. The page reports no quantified results.
Owkin is a French AI company building biology models and the K Pro AI Scientist, working with pharma on drug positioning, trial design and pathology diagnostics.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Source
Published by Owkin on its own site — read the original case study on owkin.com ↗
More like this
Related use cases
- 01Epkin used Owkin's K Pro to map prostaglandin biology and design the Phase 1 strategy for OKN4395.
- 02An oncology pharma used Owkin's K Pro and MOSAIC data to triage bispecific ADC candidates in silico.
- 03Owkin's K Pro Autopilot agent proposed a KRAS G12D drug combination that widened eligible patients from about 10% to 60%.
- 04Cleveland Clinic Abu Dhabi cut cohort assembly from days or weeks to seconds with Owkin's data transformation AI and K Pro.
- 05Owkin's MesoNet model predicts mesothelioma survival from pathology images and could shrink Phase 3 trial sizes.
- 06Compugen added Owkin's K Pro alongside its in-house target discovery AI platform.